Phase I/II radioimmunotherapy of non-Hodgkin's lymphoma with high dose 90Y-labeled humanized LL2 anti-CD-22 antibody [epratuzumab Y-90] and peripheral blood stem cell rescue
Phase of Trial: Phase I/II
Latest Information Update: 21 Jun 2011
At a glance
- Drugs Epratuzumab Y-90 (Primary)
- Indications Acute lymphoblastic leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Therapeutic Use
- 28 Feb 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov, last updated 28-2-2009.
- 10 Sep 2005 New trial record.